Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paul Palyca
Observed name:
Palyca, Paul
Observed institutions:
Lehigh Valley Health Network,
Rutgers Cancer Institute,
Binaytara
OpenAlex ID:
A5035053243
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma
2023
·
Jonathan A. Coleman
, Wesley Yip
, et al.
·
Journal of Clinical Oncology
·
112
PDF
Developments in the Treatment of Locally Advanced and Metastatic Squamous Cell Carcinoma of the Skin: A Rising Unmet Need
2014
·
Paul Palyca
, Vadim P. Koshenkov
, et al.
·
American Society of Clinical Oncology Educational Book
·
24
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded Cohort
2025
·
Viranda H. Jayalath
, Melissa Assel
, et al.
·
European Urology
·
12
Lba-17 Multicenter Prospective Phase Ii Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-grade Upper Tract Urothelial Carcinoma
2019
·
Jonathan A. Coleman*
, Nathan C. Wong
, et al.
·
The Journal of Urology
·
5
Physician knowledge, practice patterns, and barriers encountered regarding guideline‐concordant use of bone modifying agents for prostate cancer
2023
·
Aaron P. Mitchell
, Sonia Persaud
, et al.
·
The Prostate
·
2
PDF
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes
2025
·
Karen A. Autio
, Christos E. Kyriakopoulos
, et al.
·
Investigational New Drugs
·
1
PDF
Improving the use of bone modifying agents for patients with prostate cancer.
2026
·
Aaron Philip Mitchell
, Andrew L. Salner
, et al.
·
JCO Oncology Practice
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer
2025
·
Aaron P. Mitchell
, Andrew Salner
, et al.
·
JCO Oncology Practice
Variation in guideline-concordant use of bone modifying agents for prostate cancer.
2025
·
Aaron Philip Mitchell
, Andrew L. Salner
, et al.
·
JCO Oncology Practice
PDF
Disparities in Colorectal Cancer Screening Rates: A Comprehensive Analysis of Race, Ethnicity, and Insurance Status
2025
·
Shivani Modi
, Charishma Bhimineni
, et al.
·
International Journal of Cancer Care and Delivery
S3256 A Rare Case of Primary Germinoma of the Spinal Cord Causing Progressive Dysphagia
2024
·
Rachel Patel
, Amanda Jacubowsky
, et al.
·
The American Journal of Gastroenterology
Barriers to guideline-concordant use of bone modifying agents for prostate cancer.
2023
·
Aaron Philip Mitchell
, Sonia Persaud
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
14
Citation count:
155
H-index:
4
I10-index:
3
Year
Topic
Type